The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 17, 2015

Filed:

May. 17, 2012
Applicants:

Wang Shen, San Mateo, CA (US);

Wei Xiao, Jiangsu, CN;

Jack Maung, Daly City, CA (US);

Aimin Zhang, Castro Valley, CA (US);

Xiaoling Zheng, Fremont, CA (US);

Zhenzhong Wang, Jiangsu, CN;

Qingming Guo, Jiangsu, CN;

Yingguang LI, Jiangsu, CN;

Inventors:

Wang Shen, San Mateo, CA (US);

Wei Xiao, Jiangsu, CN;

Jack Maung, Daly City, CA (US);

Aimin Zhang, Castro Valley, CA (US);

Xiaoling Zheng, Fremont, CA (US);

Zhenzhong Wang, Jiangsu, CN;

Qingming Guo, Jiangsu, CN;

Yingguang Li, Jiangsu, CN;

Assignee:

NewGen Therapeutics, Inc., Menlo Park, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/54 (2006.01); A61K 31/517 (2006.01); C07D 401/00 (2006.01); C07D 239/72 (2006.01); C07D 405/12 (2006.01); C07D 493/04 (2006.01);
U.S. Cl.
CPC ...
C07D 405/12 (2013.01); C07D 493/04 (2013.01);
Abstract

The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.


Find Patent Forward Citations

Loading…